974 Results

People

  1. De Angelis
    De Angelis
  2. Yahalom
    Yahalom
  3. Abrey
    Abrey
  4. Zelenetz
    Zelenetz
  5. Perales
    Perales
  6. Horwitz
    Horwitz
  7. Schoder
    Schoder
  8. Moskowitz
    Moskowitz
  9. Noy
    Noy
  10. Portlock
    Portlock

Groups

  1. Department of Medicine (413)
  2. Hematologic Malignancies, Division of (317)
  3. Center for Hematologic Malignancies (307)
  4. Lymphoma (162)
  5. GSK Faculty (154)
  6. Survivorship Research (142)
  7. Tow Center for Developmental Oncology (TCDO) (139)
  8. Sloan Kettering Institute Faculty (133)
  9. Radiology, Department of (99)
  10. Population Sciences Research Program (94)
  1. "lymphoma"
Formats
  1. Journal Article (854)
  2. Review (54)
  3. Conference Paper (13)
  4. Editorial (13)
  5. Meeting Abstract (11)
  6. Research Letter (11)
  7. Book Section (9)
  8. Correspondence (4)
  9. Guidelines (3)
  10. Miscellaneous (2)
Groups
  1. Department of Medicine (413)
  2. Hematologic Malignancies, Division of (317)
  3. Center for Hematologic Malignancies (307)
  4. Lymphoma (162)
  5. GSK Faculty (154)
  6. Survivorship Research (142)

More Groups

People
  1. Lisa De Angelis (69)
  2. Joachim Yahalom (46)
  3. Lauren Abrey (41)
  4. Andrew Zelenetz (40)
  5. Miguel-Angel Perales (31)
  6. Steven Horwitz (28)

More People

Years
  1. 2025 (21)
  2. 2024 (43)
  3. 2023 (40)
  4. 2022 (38)
  5. 2021 (21)
  6. 2020 (36)

More Years

Publications
  1. Journal of Clinical Oncology (38)
  2. Cancer (36)
  3. Leukemia and Lymphoma (36)
  4. Blood (35)
  5. Biology of Blood and Marrow Transplantation (21)
  6. Annals of Oncology (19)

More Publications

Publishers
  1. Elsevier Inc. (127)
  2. Springer (68)
  3. Wiley Blackwell (64)
  4. Lippincott Williams & Wilkins (62)
  5. Nature Publishing Group (53)
  6. American Society of Clinical Oncology (45)

More Publishers

Results (974)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Application of the lugano classification for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The PRoLoG consensus initiative (part 2-technical)
    Journal Article

    Ricard, F.; Barrington, S.; Korn, R.; Brueggenwerth, G.; Trotman, J.; Cheson, B.; Salles, G.; Schwartz, L.; Goldmacher, G.; Jarecha, R.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Therapeutic advances in relapsed and refractory peripheral T-cell lymphoma
    Review

    Stuver, R.; Moskowitz, A. J.
    Cancers (2023)

    Fulltext@MSK | Save
  • Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The PRoLoG consensus initiative (Part 1-Clinical)
    Journal Article

    Ricard, F.; Cheson, B.; Barrington, S.; Trotman, J.; Schmid, A.; Brueggenwerth, G.; Salles, G.; Schwartz, L.; Goldmacher, G.; Jarecha, R.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • In regard to Chopade et al
    Correspondence

    Hasan, S.; Choi, J. I.; Chhabra, A.; Press, R. H.; Simone, C. B. 2nd
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/IV classical Hodgkin Lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Straus, D.; Radford, J.; Connors, J.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J.; Advani, R.; Hutchings, M.; Evens, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Joint EANM, SNMMI, and IAEA enabling guide: How to set up a theranostics center
    Review

    Herrmann, K.; Giovanella, L.; Santos, A.; Gear, J.; Kiratli, P. O.; Kurth, J.; Denis-Bacelar, A. M.; Hustinx, R.; Patt, M.; Wahl, R. L.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Delirium in critically ill cancer patients with COVID-19
    Journal Article

    Bjerre Real, C.; Dhawan, V.; Sharma, M.; Seier, K.; Tan, K. S.; Matsoukas, K.; Maloy, M.; Voigt, L.; Alici, Y.; Chawla, S.
    Journal of the Academy of Consultation-Liaison Psychiatry (2022)

    Fulltext@MSK | Save
  • Identifying participants’ preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: An adaptive choice-based conjoint analysis
    Journal Article

    Knoerl, R.; Berry, D.; Meyerhardt, J. A.; Reyes, K.; Salehi, E.; Thornton, K.; Gewandter, J. S.
    Supportive Care in Cancer (2022)

    Fulltext@MSK | Save